Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Clinical Study to Assess Efficacy, Safety and Tolerability of Orally Administered ERX1000 in Subjects With Obesity

NCT07570758 is registered in ClinicalTrials.gov with ERX Pharmaceuticals as lead sponsor.

NCT NCT07570758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07570758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Clinical Study to Assess Efficacy, Safety and Tolerability of Orally Administered ERX1000 in Subjects With Obesity
Lead sponsor
ERX Pharmaceuticals
Phase
Phase 2
Overall status
Recruiting
Start date
May 28, 2026
Completion date
May 31, 2027
Enrollment
80 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

obesity & overweight